Bronte Capital Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
Other funds holding IBB
Bronte Capital Management's IBB Position: Q3 2026 in Review
Bronte Capital Management increased its iShares Biotechnology ETF (IBB) stake by 0.62% in Q3 2026, buying an estimated $81.3K and bringing the position to 66,212 shares worth $13.9M. The position accounts for 1.4% of the portfolio, ranked #17.
Bronte Capital Management first reported a position in IBB in Q2 2022 and has held it in 18 quarters since. The position peaked at $45.4M in Q3 2025. 1,029 funds tracked by Wall St. Rank hold IBB as of Q3 2026.
- Bronte Capital Management held 66,212 shares of iShares Biotechnology ETF worth $13.9M as of Q3 2026.
- Bronte Capital Management bought 405 iShares Biotechnology ETF shares in Q3 2026, an estimated $81.3K.
- iShares Biotechnology ETF made up 1.4% of Bronte Capital Management's portfolio in Q3 2026, its #17 holding.
- Bronte Capital Management first reported a position in iShares Biotechnology ETF in Q2 2022 and has held it in 18 quarters since.
- Bronte Capital Management's iShares Biotechnology ETF position peaked at $45.4M in Q3 2025.
- 1,029 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.
Based on Bronte Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.